Overview
This page compiles documented evidence for peptide-based treatments in Havana Syndrome (Anomalous Health Incidents), focusing on Khavinson peptides and related bioregulatory therapies. The evidence draws from Russian clinical trials, mechanistic studies, and computational modeling of neurowarfare injury pathophysiology.
Clinical Trial Evidence
Semax
- Stroke Recovery: Multiple Russian trials involving hundreds of patients demonstrated improved neurological recovery in stroke survivors using Semax
- Neuroprotection: Influences over 1,500 genes involved in neuroprotection and recovery processes
- BDNF Elevation: Increases Brain-Derived Neurotrophic Factor levels by 1.4-fold within three hours of administration, with effects lasting days
GB-115
- Anxiety Reduction: 31-patient clinical trial showed Hamilton Anxiety scores reduced from 22 to 5 within three weeks
- Mechanism: Anxiolytic effects via GABAergic modulation without sedation or cognitive impairment
- Safety: No dependency issues reported; no sedative side effects
Epitalon
- Circadian Normalization: Randomized controlled trials demonstrated restoration of natural melatonin production and circadian rhythm normalization
- Target: Direct pineal gland targeting with clock gene expression regulation
Mechanistic Evidence
Computational modeling and research suggest Havana Syndrome involves four core mechanisms that peptide therapies address:
| Mechanism | Peptide Action |
|-----------|----------------|
| Neuroinflammation (elevated IL-1β) | Shift toward anti-inflammatory IL-10; suppress pro-inflammatory cytokines |
| BDNF Depletion | Semax elevates BDNF 1.4-fold within hours |
| Circadian Disruption | Epitalon restores melatonin production and clock gene expression |
| Oxidative Stress | Multiple peptides activate endogenous antioxidant systems |
Safety Evidence
- Patient Exposure: Over 15 million patients treated across Russia and Eastern Europe over four decades
- Acute Toxicity: Studies at 5,000× normal doses showed no serious reactions
- Long-term Safety: Studies at 100-1,000× regular doses revealed no adverse effects
- Side Effects: Only common side effect is occasional mild nasal irritation from intranasal delivery
Regulatory Status
| Peptide | FDA Approval | Russian Approval |
|---------|--------------|------------------|
| Semax | No | Yes (pharmaceutical) |
| GB-115 | No | Yes (supplement) |
| Epitalon | No | Yes (pharmaceutical) |
Related Pages
khavinson-peptides-havana-syndrome — Detailed overview of Khavinson peptide mechanisms and clinical applications
neurological-effects-of-microwaves — Comprehensive review of neural responses to microwave exposure including behavioral changes, cellular effects, and pharmacological analyses